The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GATO, CABA and AKBA
TSX - Toronto Stock Exchange · Copper · Molybdenum · Silver · Gold · Zinc · Lead · Germanium · Indium · Sulfur · Nickel · Platinum · Palladium
NEW YORK, NY / ACCESSWIRE / April 5, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Gatos Silver, Inc. (NYSE:GATO) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Gatos: (a) common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 28, 2020; and/or (b) securities between October 28, 2020 and January 25, 2022, inclusive. _Lead Plaintiff Deadline:_April 25, 2022
The GATO lawsuit alleges that Gatos Silver, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the technical report for Gatos's primary mine, the Cerro Los Gatos deposit, contained certain errors; (2) among other things, the mineral reserves had been overestimated by as much as 50%; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in GATO: https://www.kleinstocklaw.com/pslra-1/gatos-silver-inc-loss-submission-form?id=25598&from=1
Cabaletta Bio, Inc. (NASDAQ:CABA) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive. _Lead Plaintiff Deadline:_April 29, 2022
The CABA lawsuit alleges that throughout the class period, Cabaletta Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in CABA: https://www.kleinstocklaw.com/pslra-1/cabaletta-bio-inc-loss-submission-form?id=25598&from=1
Akebia Therapeutics, Inc. (NASDAQ:AKBA) _Class Period:_June 28, 2018 - September 2, 2020 _Lead Plaintiff Deadline:_May 13, 2022
The AKBA lawsuit alleges Akebia Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the Company's lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in AKBA: https://www.kleinstocklaw.com/pslra-1/akebia-therapeutics-inc-loss-submission-form?id=25598&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: J. Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
SOURCE : The Klein Law Firm
View source version on accesswire.com: https://www.accesswire.com/696229/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-GATO-CABA-and-AKBA